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Introduction
 Empathy is a critical interpersonal social skill that is necessary 
for everyday social communication. It helps us participate in groups, 
socialise, develop and maintain close relationships [1] and is a poten-
tial determinant of pro-social behaviours [2,3] including altruism [4]. 
Therefore, an impairment in this ability can have a significant impact 
on an individual’s mental health and well-being, and as such, under-
standing its structure, purpose and mechanism is of clinical and public 
health relevance [5]. Psychopathy [6] and related clinical disorders 
(e.g., antisocial personality disorder, conduct disorder, acquired so-
ciopathy [7] and disorders of the autistic spectrum [6,8]), have often 
been characterised by low or absent empathy for others. Prior work 
has also suggested a potential connection between the clinical charac-
teristics of autism and schizophrenia (e.g., see Bleuler’s [9] four A’s 
of schizophrenia) and as such, a body of literature has now accrued 
investigating empathy in people with a diagnosis of schizophrenia 
[10-12].
Measuring and defining empathy in schizophrenia disor-
ders
 Historically, references to empathic deficits in schizophrenia dates 
back to Bleuler [13] and Kraepelin [14], but only over the last 11 
years have researchers carried out studies comparing people with a 
diagnosis of schizophrenia and related disorders to controls without 
mental health difficulties (recruited from the general population), on 
measures purported to assess empathy. Commonly, studies have used 
the Interpersonal Reactivity Index (IRI) [15], a self-report question-
naire using four sub-scales: Fantasy, perspective-taking, personal 
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Background
 Trait empathy is integral to relationship development and main-
tenance. Therefore, impairment in this ability can have an adverse 
effect on many domains of life including social, sexual, and marital. 
Previous reviews show in schizophrenia, this ability to be impaired 
but with a high amount of heterogeneity that is yet to be explored 
more thoroughly. 
Aim and method
 Considering this, we aim to synthesise the extent literature using 
a meta-analytic approach and examine the source of the heteroge-
neity observed in previous reviews and develop taxonomy of empa-
thy deficits in schizophrenia. Hedges’ g was calculated for cognitive 
and affective empathy using random effects models. Meta-regres-
sion models of key cognitive, clinical and demographic risk and pro-
tective factors were run. These included: Impact year of publication, 
age, gender, ethnicity, education, general IQ, verbal/pre-morbid IQ, 
global neuro-cognition, positive, negative and general symptoms of 
schizophrenia, age at schizophrenia diagnosis, duration of illness 
and medication has on cognitive and affective empathy. 
Results
A literature search revealed 39 independent studies examining em-
pathy in schizophrenia. Healthy controls scored higher than people 
with a diagnosis of schizophrenia, with a small effect size for affective 
empathy (Hedges’ g = 0.29) and a medium effect size for cognitive 
empathy (Hedges’ g = 0.53). Both components were heterogeneous. 
Analyses using meta-regression models found age at diagnosis and 
the duration of illness moderated the difference in effect size for cog-
nitive empathy, such that those with an earlier diagnosis or a more 
chronic course exhibit greater difficulty in cognitive empathy com-
pared to healthy controls. 
Conclusion
 We find a longer duration of illness and younger age at clinical 
diagnosis enhances impairments in cognitive empathy in severe and 
enduring schizophrenia. For affective empathy, we conclude, com-
pared to healthy controls, some patients report having a deficit [i.e. 
experience lower affective empathy], others report comparable lev-
els, and the remaining report to be experiencing higher emotional 
arousal. As an earlier diagnosis, prolonged illness course and dys-
functional emotional reactions are significant risk factors of poorer 
empathic interactions, it will be important to address the underlying 
mechanisms of this deficit in future work. 
Keywords: Affective empathy; Cognitive empathy; Meta-Analysis; 
Schizophrenia
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distress and empathic concern. Scholars do not universally accept 
this four-component empathic conceptualisation [4,5,16-18], instead, 
suggesting empathy is better represented and measured as two inde-
pendent domains: Cognitive and affective [5]. The cognitive domain 
involves understanding and measuring the internal states of others, 
such as thoughts, intentions, and emotions [19] and the affective do-
main involves being “sensitive to and vicariously experiencing the 
feelings of others” (p. 85 [5]). 
What is known in relation to empathy and schizophrenia 
 Several meta-analyses have been beneficial in quantifying empa-
thy deficits in people with schizophrenia [10-12]. Of these reviews, 
Bonfils and colleagues [11,12] demonstrated the importance of using 
self-report and performance-based empathy measures during analy-
sis and the need to explore additional clinical characteristics (such as 
symptom severity, age at illness onset and medication) to further this 
field of research. As such, in this study, we discuss and examine for 
the first time, the moderating effect of these, and demographic (age, 
gender, education, and year of publication) and neuro-cognitive vari-
ables (i.e. global neuro-cognition, verbal/pre-morbid and general IQ), 
with the aim of assessing the sources of heterogeneity (i.e. variability) 
observed in previous reviews [11,12]. In doing this, we seek to devel-
op an evidence-based taxonomy of empathy deficits in schizophrenia. 
Empathy and Clinical Characteristics of Schizo-
phrenia 
Clinical symptoms and empathy
 Due to clinical heterogeneity, symptoms of schizophrenia have 
historically been understood in a variety of ways (for a review see 
Harrington, et al., [20]). However, reflecting the amendments made 
to the latest diagnostic manual, the DSM-5 (APA, [21]), which did 
away with sub-type specifiers (i.e. paranoid, disorganised, catatonic 
and undifferentiated) for the schizophrenia diagnosis, symptom se-
verity is now examined. Although a variety of symptom assessment 
tools are available, the Scales for the Assessment of Negative/Posi-
tive Symptoms (SANS/SAPS) [20,21] and the Positive and Negative 
Syndrome Scale (PANSS) [22] have been commonly used to assess 
positive symptoms (e.g., symptoms of delusions, hallucinations and 
disorganisation), negative symptoms (e.g., anhedonia, avolition, apa-
thy, asocialty, flattened affect and alogia) and general symptoms (e.g., 
anxiety, depression, and psychomotor symptoms) in schizophrenia. 
 In studies of empathy, the primary focus of some studies was not 
on examining symptom severity in schizophrenia [23-33]. For other 
studies, however, examining symptom severity in schizophrenia pa-
tients was included as part of secondary analyses, with mixed find-
ings reported across individual studies. For example, Montag and 
colleagues [34] found in patients, the IRI Empathic Concern related 
negatively to PANSS negative and general symptoms, Thirioux, et al., 
[35] found, using the same sub-scales, only negative symptoms asso-
ciated negatively with the IRI Perspective-Taking sub-scale. Lam, et 
al., [36] found a negative relationship between PANSS general symp-
toms and overall empathy score, and Shamay-Tsoory and colleagues 
[37] reported the degree of impaired empathy (total IRI score) de-
pended on how severe negative symptoms were. However, several 
studies reported no significant relationship between PANSS and IRI 
sub-scales [38-43] and performance-based measures of cognitive and 
affective empathy [44,45]. These discrepancies further extend to the 
SANS and SAPS symptom measurements [46-48]. Critically, these in 
consistencies have prevented the field from gaining a more nuanced 
understanding of how core symptoms of schizophrenia (i.e. positive, 
negative and general) relate to self-reported empathy. By examining 
this relationship in a meta-analytic framework, we can further our 
understanding of the mechanisms underlying empathy deficits in 
schizophrenia and develop, in a systematic manner, relevant clinical 
profiles. 
Medication 
 In the UK, for people diagnosed with a schizophrenia disorder, 
medication is recommended as the first line of treatment (National 
institute for health and social care [49]). The rationale behind this is, 
if prescribed at the correct dosage, medication can help manage acute 
symptoms, prevent relapse, and optimise level of functioning. How-
ever, whether medication also benefits interpersonal skills such as 
empathy remains unclear. Like symptom severity, the association be-
tween medication dosage and empathy (Chlorpromazine equivalent, 
mg/day) has either not been examined [26,28,34,35,38,41,50,51] or 
has shown not to correlate with components of empathy [29,32,44,47]. 
These variations may have contributed to the heterogeneity observed 
for empathy deficits in previous reviews [11,12]. Therefore, it is im-
portant that this moderator is included and examined for its effect on 
empathy further. 
Individual Differences in Empathy
Demographic variables and empathy in schizophrenia and 
related disorders
 Empathy can vary as a function of inherent psychological similar-
ities and differences between individuals, referred to in the Psycholo-
gy literature as individual differences [15]. In schizophrenia, several 
protective factors have been reported to be of benefit when re-adjust-
ing socially post-illness. These include shorter illness duration, later 
age at illness onset and female gender. Schizophrenia females have 
shown to have a better prognosis [52] and pre-morbid adjustments in 
domains of life which are integral to empathy. These include: Social, 
sexual and marital domains. Thus, females are thought to have better 
outcomes and social re-integration post-illness onset than their male 
counterpart [53-57]. As most studies in the literature have included 
predominantly male schizophrenia samples [10,24,27-33,37,39,46-
48,51,58,59], included wide age ranges [10,38,61-64] with patients 
often reporting fewer years in education compared to healthy control 
groups [23,27,41,46,50,51,58,60,65-69] and studies making a note of 
key variables such as ethnicity in patients but not necessarily exam-
ining its effect on empathy [25,27,32,36,43,44,50,51,58,66,70]. The 
current findings make it unclear as to whether demographic risk fac-
tors exacerbate deficits in empathy and consequently, in part, explain 
some of the heterogeneity observed in previous reviews [11,12]. 
Empathy and neuro-cognition in schizophrenia and relat-
ed disorders
 Neuro-cognition is central to empathy, as empathy involves mak-
ing inferences in which observation, memory, reasoning and cog-
nitive flexibility/inhibitory control are all important [28,36,37,47]. 
Broadly, neuro-cognition refers to the mental operations or process-
es used to acquire knowledge, meaning and understanding [71] of a 
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specific task or context. Experts in this field formed the Measurement 
and Treatment Research to Improve Cognition in Schizophrenia (MA-
TRICS)-as commissioned by the national institute of mental health. 
This group identified six neuro-cognitive domains: Attention, work-
ing memory (verbal and non-verbal), speed of processing, reasoning 
and problem solving, visual learning and verbal learning as import-
ant areas for further research in schizophrenia that are to be assessed 
using the MATRICS Consensus Cognitive Battery (MCCB) [72,73]. 
 In the current literature, we found only two studies to have used 
the MATRICS developed Consensus Cognitive Battery (MCCB) to 
assess all six neuro-cognitive domains [23,38]. More specifically, 
amongst the identified studies, authors have commonly produced a 
global/composite neuro-cognitive score, and examined its relation 
with empathy, with several studies finding no relationship between 
global cognition (i.e. the sixneuro-cognitive abilities) and self-re-
ported empathy in schizophrenia [23,27,38]. Other studies howev-
er, reported a positive correlation between affective empathy and 
globalneuro-cognitive scores [67]. Two studies also reported having 
assessed neuro-cognitive domains proposed by the MATRICS panel 
(i.e. working memory (verbal and non-verbal) and attention) using 
measures closely aligning to the MCCB battery [31,74]. However, as 
neuro-cognition was not the focus of these studies, this ability was not 
examined in relation to empathy. Since very few studies have exam-
ined all six of the neuro-cognitive domains proposed, examining each 
domain separately may not be possible. However, we can gather stud-
ies which have assessed anyone, or more of the neuro cognitive do-
mains identified by the MATRICS panel into a global neuro-cognitive 
score and assess its impact on cognitive and affective empathy. In this 
way, we would have sufficient studies to make provisional inferences 
relating to heterogeneity and taxonomize the role of neuro-cognition 
on empathy in schizophrenia.
 As well as neuro cognition, findings relating to Intelligent Quo-
tient (IQ) and empathy are also unclear. Two types of IQ’s have been 
measured in studies of empathy in schizophrenia: Verbal or pre-mor-
bid IQ, and general IQ. Some studies have reported subtle impair-
ments in pre-morbid/verbal IQ [29,30,50,66,74], while others have 
reported a more pronounced impairment in general IQ [36,59,67,68, 
75]. Since previous studies have found significant negative relation-
ships between measures of IQ and empathetic responding in schizo-
phrenia [23,68], it will be important to include this variable for the 
purposes of heterogeneity assessment and taxonomy development.
The goal of current research 
 Inconsistent findings have been reported for clinical, demograph-
ic and cognitive variables across studies, thereby making the under-
standing of the observed heterogeneity for empathy in previous re-
views unclear [11,12]. As such, a synthesis of the current evidence is 
timely and necessary. We, therefore, aimed to undertake a meta-anal-
ysis of the available evidence to address the heterogeneity detailed 
above. In doing this, we went beyond the basic associations detailed 
in the literature and developed an evidence-based taxonomy of empa-
thy deficits in schizophrenia.
 A meta-analytic framework was chosen as it enabled us to gather 
data systematically and provide us with a large schizophrenia sample, 
which to some extent helped us in overcoming some of the problems 
associated with small sample sizes (a common issue in this area of 
research). This meta-analysis aimed to: (1) Synthesise the extant lit-
erature on self-reported cognitive and affective empathy in schizo-
phrenia using a meta-analytic approach. (2) Examine in detail the 
heterogeneity observed in previous reviews by examining for the first 
time, the moderating effect of several important variables to create 
taxonomy. These included: Severity of positive, negative, and general 
symptoms, duration of illness, age at diagnosis, medication dosag-
es, age, gender, ethnicity, education, global neuro-cognition, verbal/
pre-morbid IQ, general IQ and year of publication on the difference 
in performance on self-reported empathy between schizophrenia pa-
tients and healthy controls. Consistent with Bonfils and colleagues 
reviews [11,12] we hypothesised that healthy controls would report 
higher levels of cognitive and affective empathy than people with a 
diagnosis of schizophrenia. Due to mixed findings in the literature for 
clinical, demographic and cognitive variables, these moderators were 
examined in an exploratory manner.
Methods
 The PRISMA (Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses) [76] checklist and literature flow chart was used 
to carry out and report findings for this study. 
Database search
 The following databases were searched electronically: Psych Info, 
Psych Article, Embase, Web of Science Core Collection and PubMed 
using the keywords (with an English language filter applied, when 
possible): Empathy, empathising, empathising, empath* appearing 
with either schizophrenia, schizoaffective, or schizo* were searched 
up until the 1st week of February 2018. References of relevant me-
ta-analyses [10-12] were also searched. In cases where a study report-
ed to have assessed empathy and met the eligibility criteria, but no 
data was provided, the corresponding author of the study wascontact-
ed (via email) for additional data. 
Study selection criteria 
 The following study inclusion criteria were used to include/ex-
clude studies: (1) Studies were required to compare people with a di-
agnosis of schizophrenia or a related disorder with a healthy (control) 
group on measures purported to assess empathy. (2) Participants had 
to be adults aged between 16 and 65 years. (3) Studies must have been 
written in the English language. (4) Studies must have measured each 
component of empathy (cognitive and affective) separately. (5) Stud-
ies had to provide sufficient data to calculate effect sizes and univari-
ate relationships. If the necessary data could not be obtained through 
available records or contact with the author, the study was excluded.
Data extraction 
 First, year of publication, publication type, country (including 
the place where the study was conducted) and the sample size was 
extracted followed by mean age, education level (in years), gender 
and ethnicity (both in percent) for schizophrenia patients and healthy 
controls. For the schizophrenia samples, medication dosage mg/day 
(chlorpromazine equivalents) [77], duration of illness (in years) and 
diagnosis (schizophrenia, schizo-affective disorder or a schizophre-
nia-related disorder) in percent were coded. Mean severity of symp-
tom score was also coded according to categories most frequently 
reported in studies: Positive, negative and general. Mean scores for 
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general IQ, verbal/pre-morbid IQ and individual neuro cognitive data 
based on the six neuro-cognitive domains (attention, speed of pro-
cessing, working memory (verbal and non-verbal), visual learning, 
verbal learning, reasoning and problem-solving) as identified by the 
MATRICS consensus panel [72,73] was coded for both, schizophre-
nia patients and healthy controls. Also, we identified a few studies 
including measures assessing cognitive flexibility/inhibitory control. 
The measures used to assess this ability were entirely different from 
the neuro-cognitive measures measuring the six domains. However, 
considering the importance of cognitive flexibility/inhibitory control 
in empathy (see for example, [3,78]) we included this as an addition-
al neuro-cognitive domain and extracted data for schizophrenia and 
healthy controls, before calculating a mean global neuro-cognitive 
score for each group. 
Effect sizes
 The effect size was computed using Hedges’g [78,79]. The mean, 
standard deviation and sample size for cognitive and affective empa-
thy for each group (schizophrenia and healthy control) were extract-
ed. In cases where this data was unavailable, but other values (e.g. 
independent sample t-value or Cohen’s d) were, then those were used 
instead. Where studies reported data for cognitive and affective em-
pathy using more than one measure, then an average study effect was 
calculated for each component to avoid multiple effect sizes per study, 
which would violate the assumption of independent observations for 
each study in a meta-analytic framework [80]. In cases where a study 
reported to have used two self-report measures of empathy, but data 
were available only for one, then the scale for which data was report-
ed/available was included. A positive value of g signified that healthy 
controls scored higher than people with schizophrenia and a negative 
value of g signified that people with schizophrenia scored higher than 
healthy controls. 
Analyses
Preliminary analyses
 Before conducting the main analyses, descriptive statistics were 
derived using SPSS version 23.0. Then, one-study remove sensitivity 
analysis was conducted to assess if anyone study effect size unduly 
affected the overall effect size for cognitive and affective empathy 
[81]. Forest plots were produced for each domain to assess for out-
liers. Visually, any effect size which looked as though it might be 
an outlier, but when examined statistically (via sensitivity analysis), 
did not differ was retained. Publication bias was examined first via 
funnel plots, then using Duval and Tweedie’s [82] Trim and Fill ran-
dom effects model. Funnel plots were created and inspected visually 
for asymmetry. The Trim and Fill approach were checked for biases 
or extreme values. If the model showed there to be no statistically 
significant difference (i.e. p >.05) between the included effect sizes, 
then we can have greater confidence that publication bias does not 
effectcurrent results [81,83]. However, in cases where the Trim and 
Fill approach showed to be statistically significant, the Fail-Safe N 
was then examined to ascertain the number of non-significant studies 
necessary to make current findings nil. 
Main analyses
 Standardised mean differences were calculated for each compo-
nent of empathy (cognitive and affective) using a Hedges’ g random 
effects model. This model was used as it accounted for both, within 
and between study variability [84]. As Hedges’ g is like Cohen’s d, the 
magnitude of the computed effect sizes was interpreted according to 
the guidelines provided by Cohen [85] such that: ≤0.20 were consid-
ered small, 0.50 were considered medium, and ≥0.80 were considered 
large effect sizes. The inverse variance was also computed to estimate 
the standard error for each effect size [84]. 
Heterogeneity and moderator analyses
 Heterogeneity was assessed using Q-statistics and degree of het-
erogeneity using I2index [83]. When Q-statistics was significant (i.e. 
p< .05), and the I2index above 25% heterogeneity could be said to 
be present and therefore, an assessment of moderator analysis proper 
[85]. Moderators were examined using a random effects meta-regres-
sion model. A moderator was of significance if there was significant 
beta-weight (p < .05) and a decrease in the I2index. 
 Barring descriptive statistics, all other meta-analytic analyses 
were conducted on Comprehensive Meta-Analysis Version 2 (CMA) 
[86].
Results
 In total, 39 studies assessing affective empathy and 36 assessing 
cognitive empathy were identified as meeting the inclusion criteria 
of this meta-analysis (See Figure 1 for the flowchart of the literature 
search).
Study characteristics
 The meta-analysis included 1,479 participants with a schizophre-
nia disorder and 1,293 healthy controls. See Tables 1-3 for detailed 
study characteristics at the individual study level and Tables 4-7 for 
aggregate study, clinical, cognitive and demographic data (Tables 
1-7).
Figure 1: Literature search diagram using PRISMA.
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Citation (K 
= 39)
Country 
(City)
SSD N HC N
% Patients in 
study with a 
Schizophrenia 
Diagnosis
M Age
SSD
M Age 
HC
% Male 
SSD
% Male 
HC
M Years in 
Education 
SSD
M Years in 
Education 
HC
% Ethnicity 
SSD
% Ethnicity HC
Achim, et al., 
[10]
Canada 
(Québec) 31 31 74.2 24.9 25.2 83.9 83.8
Andrews, et 
al., [87]
Australia 
(Victoria) 18 18 61.1 44.1 38.4 61.1 44.4 13.3 15.6
Berrada-Baby, 
et al., [88]
France 
(Versailles) 20 20 100 46.3 41.5 54.0 54.0 12.2 12.5
Brown, et al., 
[24]
USA (Balti-
more) 17 17 100 41.7 38.2 52.9 52.9
Chiang, et al., 
[68]
Taiwan 
(Hualien 
County)
70 35 100 44.5 46.0 47.1 48.0 10.9 13.0
Corbera, et al., 
[58]
USA (New 
Haven) 30 24 66.7 46.5 39.7 46.7 62.5 13.1 16.2
43.3-Caucasian 
56.5 - Non- 
Caucasian
54.2-Caucasian 
45.8-Non- Cau-
casian
Corbera, et al., 
[50]
USA (New 
Haven) 21 26 100 32.2 30.1 61.9 57.7 14.9 14.9
45.0 -Cauca-
sian 55.0- Non- 
Caucasian
42.3-Caucasian 
57.7 - Non- Cau-
casian
Derntl, et al., 
(2012a) t[44]
Germany 
(Aachen) 15 15 100 34.2 30.4 66.7 66.7 100-Caucasian 100-Caucasian
Derntl, et al., 
[70]
Germany 
(Aachen) 24 24 100 40.1 39.9 50 50.0 100-Caucasian 100-Caucasian
Didehnani, et 
al., [75]
USA (Dal-
las) 19 21 63.2 32.4 27.1 88.5 12.6 14.6
Fischer-Shofty, 
et al., [25] Israel (Haifa) 35 48 100 30.0 69.9 12.2 15.0
100-Non-Cau-
casian
100-Non -Cau-
casian
Fujino, et al., 
[39]
Japan 
(Kyoto) 69 69 100 36.6 24.2 57.9 57.9 13.9 14.5
Fujiwara, et 
al [40]
Japan 
(Kyoto) 24 20 100 37 34.6 50 50.0 13.7 14.3
Gizewski, et 
al., [26]
Germany 
(Essen) 12 12 100 37.8 36.6 100 100 9.3 9.8
Haker, et al., 
[65]
Switzerland 
(Zurich) 43 45 100 34 35.0 39.5 73.0 13 14.0
Hooker, et al., 
[23]
USA (Berke-
ley/San 
Francisco)
21 17 52 44.3 43.7 80.9 76.4 13.0 15.0
Horon, et al., 
[51]
USA (Los 
Angeles) 32 26 100 47.9 44.4 81.3 73.1 12.9 14.9
56.3 -Cauca-
sian
43.7- Non-Cau-
casian
76.0 -Caucasian
24.0- Non-Cau-
casian
Horon, et al., 
[27]
USA (Los 
Angeles and 
Chapel Hill)
145 45 100 40.9 43.3 75 71.0 12.5 14.2
48.3-Caucasian 
51.7-Non-Cau-
casian
31.0 -Caucasian
69.0- Non-Cau-
casian
Kucharska-Pi-
etura, et al., 
[61]
Poland 
(Lublin) 100 50 100 31.3 29.6 12.8 13.7
Lam, et al., 
[36]
China (Hong 
Kong) 58 61 100 40.1 41.3 50 50.8 10.4 11.3
100-Non- Cau-
casian
100-Non-Cau-
casian
Lee, et al., [28] South Korea (Seoul) 15 18 100 26.0 25.8 46.6 50.0 15.1 15.4
Lee, et al., [69] USA (Los Angeles) 30 22 100 46.1 44.3 83.3 77.2 12.8 14.7
Lehmann, et 
al., [29]
Germany 
(Berlin) 55 55 100 39.8 38.9 58.1 54.5 14.0 15.0
Matsumoto, et 
al., [30]
Japan 
(Kyoto) 17 18 100 40.0 35.0 35.0 66.6
McCormick, et 
al., [48]
USA (Iowa 
City) 16 16 88 37.0 36.6 88 87.5 13.9 15.4
McGuire, et 
al., [31]
Australia 
(Sydney) 24 20 83 46.6 38.6
McGuire, et 
al., [74]
Australia 
(Sydney) 45 27 43.7 40.7 82.2 62.9
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Table 1: Individual demographic characteristics of the studies included in the meta-analysis.
Note: SSD = Schizophrenia-Spectrum Disorder Sample; HC = Healthy Control Sample; M = Mean. tSupplemental information was provided by authors to 
assist in the coding of these studies.
Montag, et al., 
[42]
Germany 
(Berlin) 45 45 100 37.5 38.8 77.7 77.7 12.6 15.0
Montag, et al., 
[58]
Germany 
(Berlin) 145 145 97 36.9 37.2 62.7 54.4 13.0 15.1 100-Caucasian 100-Caucasian
Pijnenborg, et 
al., [60]
The 
Netherlands 
(Groningen)
46 53 100 27.4 31.1 73.0 46.0
Ramos-Loyo, 
et al., [62]
Mexico 
(Guadala-
jara)
38 38 100 36.1 34.2 47.3 47.3 13.1 13.8
Regenbogen, 
et al., [43]
Germany 
(Aachen) 20 24 100 37.3 35.2 54.1 65.0 11.5 12.3
Smith, et al., 
[47]
USA (Chi-
cago) 45 60 100 35.3 33.0 63.3 53.3
43.3- Caucasian 
56.7-Non-Cau-
casian
48.9- Caucasian 
51.1-Non-Cau-
casian
Singh, et al., 
[32]
India (New 
Delhi) 14 14 100 31.5 27.2 78.5 71.4 9.6 11.3
100-Non-Cau-
casian
100-Non-Cau-
casian
Sha-
may-Tsoory, et 
al., [37]
Israel (Haifa) 26 31 100 26.6 69.2 51.6
Sparks, et al., 
[46]
Australia 
(Sydney) 28 25 89 45.9 35.7 57.1 40.0 13.2 16.7
Thirioux, et 
al., [35]
France 
(Paris) 10 10 100 33.3 32.5 100 100 11.8
Vistoli, et al., 
[59]
Canada 
(Québec) 27 21 67 29.7 29.2 85.1 80.9
Wojakiewicz, 
et al., [33]
France 
(Paris) 29 27 100 36.5 31.0 68.9 74.0 10.3 10.5
Citation (K = 39) Country (City) M Age at Di-agnosis
M Duration 
of Illness
M Medication Dosage 
(Chlorpromazine equiv-
alents) – mg/day
M Positive Symp-
tom Severity Score
M Negative Symp-
tom Severity
Score
M General Symptom 
Severity Score
Achim, et al., [10] Canada (Québec) - 1.7 - 15.1 16.0 32.0
Andrews, et al., t[87] Australia (Victoria) 21.4 21.1 - - - -
Berrada-Baby, et al., [88] France (Versailles) - - 406.0 - - -
Brown, et al., [24] USA (Baltimore) 30.5 9.3 - 19.1 24.9 45.4
Corbera, et al., [58] USA (New Haven) 24.3 22.2 654.0 18.9 N-17.0 30.2
Corbera, et al., [50] USA (New Haven) - - 181.3 15.2 15.2 29.2
Derntl, et al., [44] Germany (Aachen) 26.8 7.3 329.9 12.3 14.6 24.5
Derntl, et al., [70] Germany (Aachen) 28.9 11.5 601.4 14.0 14.2 28.9
Didehnani, et al., [75] USA (Dallas) - - - 18.9 16.5 37.1
Fischer-Shofty, et al., [25] Israel (Haifa) - 11.8 - 15.4 19.3 34.5
Fujino, et al., [39] Japan (Kyoto) 24.2 13.1 - 14.2 15.9 31.4
Fujiwara, et al., [40] Japan (Kyoto) 26.9 10.4 - 14.3 13.9 32.7
Gizewski, et al., [26] Germany (Essen) 21.0 16.8 672.3 14.6 20.5 31.9
Haker, et al., [65] Switzerland (Zurich) 24.0 11.0 297.0 12.2 14.6 26.3
Hooker, et al., [23] USA (Berkeley/San Francisco) - 24.5 - 11.7 16.5 -
Horon, et al., [51] USA (Los Angeles) 20.8 26.8 282.5 1.5 1.7 -
Horon, et al., [27] USA (Los Angeles and Chapel Hill) 21.0 20.0 - 2.5 2.1 -
Kucharska-Pietura, et 
al., [68] Poland (Lublin) - 8.6 408.1 39.4 59.8 -
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Lam, et al., [36] China (Hong Kong) 25.9 13.4 - 9.7 13.3 20.6
Lee, et al., [28] South Korea (Seoul) 21.7 4.6 422.1 13.1 15.4 30.6
Lee, et al., [68] USA (Los Angeles) - - - 5.9 5.3 -
Lehmann, et al., [29] Germany (Berlin) 29.8 10.0 407.8 13.2 15.9 -
Matsumoto, et al., [30] Japan (Kyoto) - 15.2 - 16.1 6.6 10.6
McCormick, et al., [48] USA (Iowa City) 20.7 15.8 - 4.6 9.2 -
McGuire, et al., [31] Australia (Sydney) 22.5 22.7 - 1.3 2.1 -
McGuire, et al., [73] Australia (Sydney) 21.6 21.80 - 1.7 2.1 -
Montag, et al., [42] Germany (Berlin) 25.8 11.6 - 19.7 19.7 -
Montag, et al., [58] Germany (Berlin) 26.5 10.4 453.8 17.0 19.4 35.6
Pijnenborg, et al., [60]
The Netherlands 
(Groningen) 24.2 7.0 - 12.8 15.3 29.2
Ramos-Loyo, et al., [62] Mexico (Guadalajara) - 23.4 200.0 16.9 17.8 28.9
Regenbogen, et al., [43] Germany (Aachen) 27.8 9.5 - 14.2 23.1 -
Smith, et al., [47] USA (Chicago) - 14.4 360.9 0.6 0.6 -
Singh, et al., [32] India (New Delhi) 23.7 9.3 389.3 8.6 12.6 -
Shamay-Tsoory, et al., [37] Israel (Haifa) - - - 16.5 21.0 -
Sparks, et al., [46] Australia (Sydney) - - 300.9 38.8 39.3 --
Thirioux, et al., [35] France (Paris) - 11.8 664.4 21.6 32.2 -
Vistoli, et al., [59] Canada (Québec) - 7.6 547.7 16.0 9.6 -
Wojakiewicz, et al., [33] France (Paris) - 8.0 - 14.2 19.2 -
Table 2: Clinical data coded for patients with schizophrenia spectrum disorders from individual studies included in the meta-analysis.
Note: M = Mean; CPZ-equivalent-mg/day = Chlorpromazine Equivalent in milligram per day. tSupplemental data was provided by authors. M = Mean. 
In this table, only that study for which data was available is included.
M General IQ Score 
in SSD
M General 
IQ Score in 
HC
M Pre-morbid/
Verbal IQ Score 
in SSD
M Pre-morbid/Verbal 
IQ Score in HC
M Global Neuro-cogni-
tion Score in SSD
M Global Neu-
ro-cognition Score 
in HC
Achim, et al., [10] 100.4 101.8 - - - -
Berrada-Baby, et al., [87] - - 26.5 28.9 - -
Chiang, et al., [68] 83.9 100.4 - - - -
Corbera, et al., [58] - - - - 39.6 52.0
Corbera, et al., [50] 89.5 - - - 32.1 32.0
Derntl, et al., t[44] - 114.2 30.2 32.0 - -
Derntl, et al., [70] - - 107.7 111.3 - -
Didehnani, et al., [75] 102.2 112.1 - - - -
Fujino, et al., [39] - - 103.1 105.3 - -
Fujiwara, et al., [40] 104.0 109.0 104.0 107.0 - -
Gizewski, et al., [26] - - 102.2 109.8 - -
Haker, et al., [65] - - 24.4 33.1 16.8 22.5
Hooker, et al., [23] 101.1 - - - -0.32 0.4
Kucharska-Pietura, et al., [61] - - - - 24.4 37.4
Lam, et al., [36] 34.9 49.8 - - 16.6 20.4
Lee, et al., [28] - - 11.4 12.7 14.5 10.4
Lehmann, et al., [29] - - 108.5 118.8 25.0 21.9
Matsumoto, et al., [30] - - 101.7 107.9 - -
McGuire, et al., [31] - - 105.6 107.7 35.1 37.5
McGuire, et al., [74] - - 103.0 109.5 27.9 33.5
Montag, et al., [42] - - 25.8 29.6 - -
Montag, et al., [58] - - 103.9 108.9 - -
Pijnenborg, et al., [60] 90.2 103.4 41.9 52.1 36.3 31.3
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Mean (SD)/Mean 
Percent (SD)
Range K
Sample Type
Published Article 94.9 - 37
Poster (data from authors) 5.1 - 2
Year 2012 2007-2017 39
SPD Sample Size 37.9 (31.4) 10-145 39
HC Sample Size 33.2 (23.9) 10-145 39
Location
Europe 33.3 - 13
United States 33.3 - 13
Asia 23.2 - 9
Oceania 10.3 - 4
Table 4: Study characteristics of included studies in the meta-analysis.
Note: Standard Deviation; K = Number of studies included; SPD = Schizo-
phrenia Spectrum Disorders; HC = Healthy Control.
Mean (SD)/Mean 
Percent (SD)
Range K
Diagnosis
Schizophrenia 93.2 (13.6) 52.4-100 38
Shizo-affective 4.65 (15.6) 2.7-42.9 10
Other Psychoses 1.86 (9.2) 6.3-19.3 2
Age at Diagnosis 24.6 (3.1) 20.7-30.5 22
Duration of Schizophrenia 13.5 (6.3) 1.7-26.8 32
Symptom Severity
Positive Symptoms 13.9 (8.4) 0.61-39.40 36
Negative Symptoms 16.6 (10.9) 0.66-59.80 36
General Symptoms 31.0 (5.3) 20.6-45.4 18
Medication Dosage (Chlorprom-
azine equivalents) – mg/day 414.3 (38.02) 162.1-642.3 18
Table 5: Clinical characteristics of samples included in the meta-analysis.
Note: SD = Standard Deviation; K = Number of studies included
Regenbogen, et al., [43] - 71.4 82.1 22.3 17.7
Smith, et al., [47] - - - - 0.32 0.4
Sparks. et al., [46] - - 104.9 110.0 - -
Thirioux, et al., [35] - - - - - -
Vistoli, et al., [59] 99.9 109.3 - - - -
Wojakiewicz, et al., [33] 90.3 93.6 - - -- -
Table 3: Mean general IQ, pre-morbid/verbal IQ and global neuro cognitive scores for schizophrenia spectrum disorders and healthy controls coded from 
individual studies included in the meta-analysis.
Note: M = Mean; CPZ-equivalent-mg/day = Chlorpromazine Equivalent in milligram per day. tSupplemental data was provided by authors. M = Mean. 
In this table, only that study for which data was available is included.
Mean (SD)/Mean 
Percent (SD)
Range K
General IQ, Healthy Controls 99.29 (19.6) 49.8-14.2 9
General IQ, Schizophrenia 
Spectrum Disorder 89.6 (20.4) 34.9-04.0 10
Verbal/Pre-morbid IQ, Healthy 
Controls 79.9 (40.7) 12.7-18.8 15
Verbal/Pre-morbid IQ, Schizo-
phrenia Spectrum Disorder 74.9 (39.7) 11.4-08.5 15
Global Neuro-cognition, Healthy 
Controls 24.4 (15.03) 0.43-52.1 13
Global Neuro-cognition, Schizo-
phrenia Spectrum Disorder 22.3 (12.6) -0.32-39.5 13
Table 6: Cognitive characteristics of samples included in the meta-analysis.
Note: SD = Standards Deviation K = Number of studies included.
Demographic variables
Mean (SD)/Mean 
Percent (SD)
Range K
Age, Healthy Controls 35.2 (5.9) 24-46 39
Age, Schizophrenia Spectrum 
Disorders 37.8 (6.1) 25-48 38
Education, Healthy Controls 14.0 (1.7) 9.8-16.7 27
Education, Schizophrenia Spec-
trum Disorders 12.5 (1.3) 9.3-15.1 28
Male, Healthy Controls 63.9 (15.2) 40-100 36
Male, Schizophrenia Spectrum 
Disorder 67.5 (15.6) 47-100 36
Ethnicity, Healthy Controls
Caucasian-69.1 (28.6)
Non-Caucasian- 31.3
(28.1)
31-100
24-100
8
7
Ethnicity, Schizophrenia Spec-
trum Disorder
Caucasian-67.0 (27.6)
Non-Caucasian-33.0 
(24.8)
43.3-100
43.7-100
8
8
Table 7: Demographic characteristic of samples included in the meta-anal-
ysis.
Note: SD = Standard Deviation; K = Number of studies.
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Empathy measures
 The Interpersonal Reactivity Index (IRI) [19] was used in 87.2% 
(k = 34) of included studies. Besides this, five studies [37,60,61,63,75] 
used The Empathy Quotient [89], Balanced Emotional Empathy Scale 
[89], Questionnaire Measure of Emotional Empathy [90] and Social 
Context Emotional Recognition Task [62] respectively (Supplemen-
tary Table S1 for a description of the empathy measures included). 
Symptom assessment
 Symptoms of schizophrenia was assessed in 92.3% (k = 36) of 
included studies. Assessment tools included the PANSS [22]; SAPS 
[91]; SANS [92] and the Brief Psychiatric Rating Scale (BPRS) [93] 
(Supplementary Table S2). 
Assessment of neuro-cognition 
 Broadly, data for neuro-cognition was available for k = 13 studies. 
We identified several studies assessing neuro-cognition [37,44,51,70] 
for which we could not gather the required data within our data col-
lection timeframe. 
 One study [58] measured all six neuro-cognitive domains (i.e. at-
tention, speed of processing, working memory (verbal and non-ver-
bal), visual learning, verbal learning, reasoning and problem solving) 
using the Measurement and Treatment Research to Improve Cog-
nition in Schizophrenia (MATRICS) Consensus Cognitive Battery 
(MCCB) [94]). Barring the attention domain, Hooker, et al., [23] also 
measured the above-mentioned domains using the MCCB. Although 
Smith and colleagues [47] reported not to have used the MCCB bat-
tery, nonetheless assessed the six neuro-cognitive domains using ap-
proximate measures representing the MCCB assessment battery [94]. 
Across the remaining ten studies [29,31,36,43,51,60,61,65,69,74] 
few, but not all six neuro-cognitive domains were assessed using tests 
that differed from but comparable to the MCCB. For example, Lam, 
et al., [36] assessed the reasoning and problem solving, and visual 
learning domain, whereasother studies (see for example, [61]), as-
sessed the attention and working memory (non-verbal) domain. We 
also found few studies [31,51,65,88] to have examined cognitive flex-
ibility, which we additionally included within the global neuro-cog-
nitive moderator (Supplementary Table S3 for a description of the 
neuro-cognitive measures used in individual studies and the corre-
sponding neurocognitive domain examined).
 In total, 15 studies measured pre-morbid/verbal IQ. Pre-mor-
bid/verbal IQ was measured in 13 of these studies using either the 
Multiple-choice vocabulary test (German version) (MCVT; [95]) 
or National Adult Reading Test (NART; [96]). MCVT was includ-
ed by seven studies [26,29,42-44,58,70] and NART by six studies 
[30,31,39,46,73,74,88]. The remaining two studies [28,40] used the 
verbal sub-set from the Wechsler’s Adult Intelligence Scale - III [97] 
(Supplementary Table S4 for a short description of each of the verbal 
task used by the included studies). 
 Data for general IQ was available for ten of the included stud-
ies. Eight of these studies [10,23,33,40,50,59,68,75] used several 
versions of the Wechsler’s Adult Intelligence Scales (e.g. [97]). The 
remaining two studies [36,60] used the Raven’s Progressive Matrices 
 
Test (120) and Groninger Intelligence Test [98] respectively (Supple-
mentary Table S5 for a description of the general IQ measures used 
by the included studies). 
Sensitivity analysis
 One study removed sensitivity analysis, and visual assessment of 
forest plots (available on request from the author) was carried out 
for the effect sizes for cognitive and affective empathy separately. 
We found, when the point effect size for each study was removed 
the overall mean effect sizes for each component of empathy did not 
differ significantly. Thus, all studies were retained for the main me-
ta-analysis.
Meta-analyses 
 For cognitive empathy, a medium effect size (k =36, Hedges’ g = 
0.53, 95% CI [0.43, 0.64], p<0.001) was found, such that the healthy 
control group reported to have better perspective-taking ability then 
the schizophrenia group (Figure 2). The Q-statistics was significant 
(Q-statistics = 52.88, df = 35, p = .02) with an I2 index of 33.82%.
 For affective empathy, a small effect size was found (k = 39, Hedg-
es’ g = 0.29, 95% CI [0.16, 0.42], p<0.001) (Figure 3). This indicated 
the healthy control group had better affective empathic ability than 
the schizophrenia group. The Q-statistic was significant (Q-statistic = 
98.21, df = 38, p<0.001) with an I2 index of 61.31%.
Meta-analyses examining impact of co-morbid psychiatric 
condition on empathy
 We ran additional meta-analyses, excluding studies including 
schizo-affective patients. For cognitive empathy, the effect size 
remained medium (k = 26, Hedges’ g = 0.51, 95% CI [0.39,0.63], 
p<0.05) and for affective empathy, it remained small (k = 29, Hedges’ 
g = 0.24, 95% CI [0.12,0.30], p<0.05). Thus, all samples were re-
tained for subsequent analyses. 
Figure 2: Forest plot of studies included in the cognitive empathy me-
ta-analysis (k = 36).
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Moderator analyses
 The clinical characteristics: Duration of illness (in years), age at 
diagnosis (in years) mean symptom severity score (positive, nega-
tive and general), and medication dosage (mg/day) (chlorpromazine 
equivalents). Neuro-cognition: Mean general, verbal/pre-morbid and 
global neuro-cognition score, and demographic variables: Mean age 
of schizophrenia patients (in years), gender (higher percent of schizo-
phrenia male samples), education (lower educational attainment in 
schizophrenia) (in years), ethnicity (higher percent of non-Caucasian 
compared to Caucasian schizophrenia patient) and year of study pub-
lication were examined as continuous moderators for each domain of 
empathy. 
Cognitive empathy
 Meta-regression found the duration of illness significantly mod-
erated the difference between samples (i.e., schizophrenia vs healthy 
controls) on measures of cognitive empathy. Such that for every one-
year increase in duration of illness, the standardised mean difference 
in performance between schizophrenia and healthy controls increased 
by 0.012. This significant finding was accompanied by a decrease in 
the I2index to 3.27%. Thus, the duration of illness explained 30.55% 
of the initially observed I2index. Age at diagnosis was also found to 
negatively moderate the difference in performance between patients 
and controls, such that as the age of symptom onset decreased, dif-
ferences in performance between the two groups increased by -0.06 
points. This effect was accompanied by a decrease in the I2 index by 
5.12%, thus explaining 28.70% of the initially observed I2index (Ta-
ble 8). Besides this, none of the other moderators reached statistical 
significance (Table S6-S8).
Affective empathy
 Meta-regression analyses found none of the clinical, cognitive and 
demographic moderators reached statistical significance (Table S9-
S11). 
Publication bias
 For affective empathy, the Trim and Fill approach [81] identified 
four missing studies, with the effect size increasing to Hedges’ g = 
0.37 (p<0.05). However, the classic fail-safe N identified that we 
would need 409 missing studies to bring the p-value of the current 
observed effect size to non-significance. For cognitive empathy, nine 
studies were identified as missing, with the effect size reducing to 
Hedges’ g = 0.41 (p <0.05). Here the fail-safe N identified 1,367 
non-significant studies necessary to bring the current effect size to nil 
(see Figures 4 and 5 for the funnel plots with imputed studies).
Discussion
 As well as synthesising the extant literature on empathy in schizo-
phrenia, this study considerably expanded past work by examining 
the moderating effect of clinical (positive, negative, general, medi-
cation effect, age at diagnosis and duration of illness), demograph-
ic (age, gender, education, ethnicity and year of publication) and 
Figure 3: Forest plot of studies included in the affective empathy me-
ta-analysis (k = 39).
k B SE 95% CI Z P Reduc-tion in I2
Age at 
Diagnosis 20 -0.06 0.018 [-0.09, -0.02] -3.35 0.0008 28.7
Duration of 
Illness 29 0.01 0.008 [0.001,0.03] 2.11 0.03 30.6
Table 8: Significant moderator variables for cognitive empathy.
Figure 5: Funnel plot showing the standard error for the effect sizes (Hedg-
es’ g) for the cognitive empathy meta-analysis (k = 36). The trim and fill 
procedure imputed nine studies in total.
Figure 4: Funnel plot showing the standard error for the effect sizes (Hedg-
es’ g) for the affective empathy meta-analysis (k = 39). The trim and fill 
procedure imputed four additional studies.
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cognitive (verbal/pre-morbid IQ, general IQ and global neuro-cogni-
tion) variables on cognitive and affective empathy. In doing this, we 
went beyond examining basic associations observed in the literature 
and developed an evidence-based taxonomy of empathy in schizo-
phrenia. Consistent with our hypotheses, we found, healthy controls 
reported higher levels of affective empathy than schizophrenia pa-
tients (a small effect size). For cognitive empathy, the difference in re-
porting between the two groups was of a medium effect, with healthy 
controls reporting higher perspective-taking ability then the patient 
group. Amongst the variables studied, duration of illness and age at 
illness onset significantly moderated the difference in performance 
between patients and controls on measures of cognitive empathy. Be-
sides these, none of the other moderators reached statistical signifi-
cance. The effect sizes reported in this study are in line with previous 
reviews on this topic [11,12]. 
Moderating Effect of Clinical variables on Empathy
Duration of illness and empathy 
 For the moderating effect of duration of illness, we found, for ev-
ery one-year increase in illness duration, the difference in perspec-
tive-taking ability between patients and healthy controls increased by 
0.012 points. This observation is consistent with a previous meta-anal-
ysis on this topic [12]. Adding further, we found this effect to be inde-
pendent of any age-related decline in schizophrenia. Cross-sectional 
studies are the norm rather than the exception in this field of research. 
However, as the current evidence points to a progressive decline in 
self-reported cognitive empathy, our findings can be said to provide 
indirect, longitudinal evidence of deterioration over time. This can 
be explained by several reasons. For example, the distress caused by 
psychotic thinking, perhaps due to poorer clinical insight can make 
people with a diagnosis of schizophrenia mistrustful of others, which 
in turn could lead to social withdrawal [99] or a restriction in their 
social network [100]. Over time, this can lead to patients having fewer 
opportunities to socialise and hone their empathic skills, thus increas-
ing the probability of empathic atrophy over time. Besides this, long-
term residual symptom experiences, medication side-effects, sensitiv-
ity to stress, and substance misuse may also affect key cortical regions 
associated with empathy [23,32,39]. High level of stigma associated 
with schizophrenia [101], as well as a loss of morale and self-esteem 
over time can also lead to a loss of hope, confidence and motivation in 
people with schizophrenia [102], all of which can negatively impede a 
patient’s ability to engage confidently or communicate effectively in 
an empathetic manner. 
 Age at clinical diagnosis also had a moderating effect on cog-
nitive empathy. As the age at diagnosis decreased, the difference in 
performance between patients and controls on self-reported cognitive 
empathy increased. This means that those with an earlier diagnosis-
reported havinggreater difficulties in perspective-taking then those 
whose symptom onset was at a later age. Duration of illness and age at 
diagnosis are related. Both are reliable indicators of severity of illness 
in schizophrenia (i.e. the earlier the onset, the worse it is regarding 
functional outcome, and the longer it persists without remission, the 
less likely you are to improve) [103]. Therefore, it will be important 
to address the underlying mechanisms of this deficit in future work. 
Clinical symptoms and empathy 
 We found none of the schizophrenia symptoms (i.e., positive, 
negative and general symptoms) moderated the effect sizes for cogni-
tive or affective empathy. Amongst the included studies (k = 39), only 
a few studies reported a significant association between severity of 
clinical symptoms and empathy [37,46,47,51,58,61,62], with several 
studies not finding any statistically significant relationship between 
either one of the core schizophrenia symptoms and self-reported em-
pathy [10,23,29,32,36,39,40,47,42,43,58,65,70,88]. A closer inspec-
tion of the clinical profile of the schizophrenia group we were analys-
ing indicated that this group was on a stable dosage of antipsychotics 
at the time of testing and were, therefore, only really experiencing 
symptoms residually (Table 5). Therefore, a restricted range in the 
symptom severity score or the fact that most patients were not ex-
periencing symptoms acutely could explain the lack of relationship 
with empathy. 
 We found no moderating effect of chlorpromazine equivalents (mg/
day) on self-reported cognitive and affective empathy. These findings 
are consistent with studies that directly compared the effects of chlor-
promazine equivalent on self-reported empathy [29,32,44,46,47]. 
These findings also extend to haloperidol equivalents [32,39,40]. 
Singh, et al., [32] also reported having found no effect of duration 
of antipsychotic drug taken on any of the IRI scores in an enduring 
schizophrenia sample. Also, in one of the largest sample study com-
paring patients treated on conventional versus atypical antipsychotic 
drugs on social cognitive abilities, Kucharska-Pietura and colleagues 
[61] found no clear advantage of atypical antipsychotics over typical 
antipsychotics on emotional functioning in patients with schizophre-
nia. Results from several longitudinal studies [104] have also indi-
cated no significant effect of antipsychotic drug treatment on several 
other related social-cognitive domains (e.g. facial affect perception). 
Thus, it appears that while antipsychotic drugs are useful in treating 
core symptoms of schizophrenia, deficits in empathy may perhaps be 
resistant to pharmacological intervention. 
Demographic variables and empathy 
 This study included many studies which provided us with a large 
sample to examine several demographic variables more thoroughly. 
These included; the impact of age-related decline, a higher proportion 
of male patients (compared to female patients), ethnicity (higher pro-
portion of non-Caucasian schizophrenia patients compared to Cauca-
sian patients), and lower educational attainment in the schizophrenia 
group (compared to the healthy group), on self-reported cognitive 
and affective empathy. None of these demographic variables directly 
moderated the difference in performance between patients and con-
trols on self-reported measures of empathy, which is consistent with 
several independent studies in the literature. In relation toage, several 
studies included this variable as a covariate and consistent with the 
current findings, found schizophrenia patients and controls continued 
to differ on empathic abilities [46,75]. Similarly, a direct examination 
of gender-related effects in schizophrenia patients, on measures of 
cognitive and affective empathy, also revealed no significant interac-
tion [39,40,58,105] or any impact of lower education attainment on 
empathy [36,46,61,68]. Collectively, these findings suggest other risk 
factors not observed here may have superseded current demographic 
risk factors in patients with schizophrenia. 
Neuro-cognition and empathy
 Several neuro-cognitive variables were examinedin relation toem-
pathy. These included: Verbal/pre-morbid IQ, general IQ and global 
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neuro-cognition. Regarding general and pre-morbid/verbal IQ, nei-
ther variable moderated the differences in performance between pa-
tients and controls. This finding is consistent with several studies in 
which differences on measures of empathy remained between groups 
of interest after controlling for these initial differences [40,42,75]. To-
gether these findings indicate, that while impairments in general and 
verbal/pre-morbid IQ remain apparent in patients with more severe 
and enduring schizophrenia [29,30,36,38,58,59,60,68,74,75] they do 
not adequately account for the heterogeneity observed in empathy in 
this or previous reviews [12]. 
 In this study, instead of examining individual neuro-cognitive do-
mains, we examined what we termed ‘global neuro-cognitive abili-
ties’ by including studies that assessed all, few or one of the six neu-
ro-cognitive domains defined and recommended by the MATRICS 
panel [72,73] as well as an additional, cognitive flexibility/inhibitory 
control domain. Overall, we did not find any impact of this variable 
on cognitive or affective empathy which is consistent with several of 
the published studies in the field [23,27,58]. However, as it is well 
established that like IQ, neuro-cognitive deficits do exist in patients 
with more severe and enduring schizophrenia [106] and is an essen-
tial component of empathy [31,36,47,51,74]. Therefore, the lack of 
association is somewhat surprising. It may be that this moderator 
was somewhat underpowered, or there was a lack of dispersion in 
the neuro cognitive scores. Alternatively, it may have been that for 
neuro-cognitive abilities to relate to empathy; tasks need tapping into 
specific cognitive abilities. In other words, specific executive function 
tasks (e.g. emotion-regulation) relating to empathy [78,101] is per-
haps necessary to find a significant effect. 
Affective empathy and heterogeneity
 For affective empathy, we found, healthy controls reported high-
er affective empathy then schizophrenia patients, with a small effect 
size (Hedges’ g = 0.29) with significant heterogeneity (I2 = 61.31%), 
both findings are consistent with previous reviews in the field [11,12]. 
However, none of the moderators we examined explained the ob-
served heterogeneity. This may be due to variability in the affective 
responses by the included patients. Across individual studies, we 
found, three affective responses: (1) Some patients reported to have 
deficits in affective empathy (i.e. lower levels than healthy controls) 
[26-29,31-33,36,37,47,51,58,68,69,74]. (2) Other studies reported 
comparable levels of affective empathy in schizophrenia patients 
and healthy controls [10,24,39,59,60,62] and (3) the remaining, re-
ported higher levels of affective empathy in patients than in controls 
[27,29,30,35,43,50,88]. Thus, under the rubric of schizophrenia, sev-
eral affective responses may have been present, which could explain 
both, the small effect size and lack of moderator influence found in 
this study. 
Limitations
Publication bias
 We found an interesting effect of publication bias on current 
findings. For affective empathy, we found that the missing stud-
ies increased the overall effect size from the observed Hedges’ g = 
0.29 to Hedges’ g = 0.37. In the studies we included, we found, pa-
tients were medically stable at the time of testing (symptom severity 
score; Table 5). The nature of some symptoms, especially negative 
symptoms means social withdrawal and anhedonia are common, and 
as such, patients with these experiences are unlikely to participate 
in research studies. Therefore, for affective empathy, the publication 
bias is perhaps reflective of missing studies of patients with predom-
inantly negative symptoms where deficits in affective empathy are 
likely to be more pronounced. 
 For cognitive empathy the opposite held. In total, nine studies 
were identified as missing (Figure 5) and including them would have 
reduced the effect size from Hedges’ g = 0.53 to Hedges’ g = 0.41. 
This observation is consistent with a previous meta-analysis in the 
field [12] and together highlight two important issues: (1) The need to 
also publish nil findings and (2) where possible, include schizophre-
nia samples at different stages of the illness course, particularly at the 
earlier phase, where deficits in perspective-taking are likely to be less 
pronounced then in the more severe and enduring phase.
Measures of empathy: Self-report
 Our findings for empathy are reported from self-report measures. 
Thus, they must be interpreted as showing how patients perceive their 
abilities as opposed to their actual abilities, which may differ [11]. 
We did not include performance-based measures since few studies 
have been published and a lack of psychometric properties was avail-
able for those measures [33]. Moreover, self-reported measures are 
more acceptable to patients, and since they tap into a wide range of 
situations, they are more apt in providing broader estimates of empa-
thy levels than other measures (e.g. performance-based) which evalu-
ate responses to specific circumstances.
Impact of additional variables
 The impact substance misuse (drugs and alcohol), co-morbid med-
ical illness, and family history of psychiatric illness has on self-re-
ported empathy was not be examined as no or insufficient data was 
available for these variables. Nonetheless, these are important vari-
ables commonly found to affect patients with a diagnosis of schizo-
phrenia [23,26,32,39] and may have therefore conflated current find-
ings. Thus, it is important that readers take this into account when 
interpreting current results and report on these additional variables in 
future work. 
Generalisability of current findings
 We did not find any impact of year of publication on reported ef-
fect sizes. This means, over the years, there have been no significant 
changes in the methodology and samples recruited. We found schizo-
phrenia samples in this, and previous reviews [10-12], can be classi-
fied as ‘stereotypical schizophrenia samples’. This includes a predom-
inantly chronic, male sample, on medication, with core schizophrenia 
symptoms stable, with minimum (if any) negative symptoms. Since 
schizophrenia is a heterogenous syndromic disorder, care must be 
taken in term of the extent to which we generalise current findings to 
other phases or schizophrenia samples.
 Also, over 90 percent of the studies included were conducted in 
developed countries (Table 1). Better outcomes have been found in 
many developing compared to developed countries [101]. Thus, find-
ings from this study may not be fully general is able to those recover-
ing in developing countries.
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Conclusion
 In conclusion, we found a prolonged illness course or earlier di-
agnosis taxonomized deficits in cognitive empathy in patients with 
enduring schizophrenia. For affective empathy, we conclude, some 
patients report a deficit; others report comparable levels to healthy 
controls, and the remaining report experiencing higher emotional 
arousal then healthy controls. As an earlier diagnosis, prolonged ill-
ness course and dysfunctional emotional reactions are significant risk 
factors of poorer empathic interactions; it will be important to address 
the underlying mechanisms of these deficits in future work. 
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Measures of Empathy
Original 
Article
Studies in Me-
ta-Analysis
Description of Tasks and Scores Produced
Interpersonal Reactivity 
Index (IRI) [1] [2-35]
A 28-item self-report scale including four sub-scales: Empathic Concern, Perspective-Taking, Personal Distress and Fan-
tasy. The Empathic Concern sub-scale taps into ‘other-orientated’ feelings of sympathy and concern for unfortunate other. 
The Perspective-Taking sub-scale assesses the ability to see things from the others perspective or how the other person 
thinks. The Personal Distress sub-scale measures levels of anxiety, sorrow or emotional distress in emergency situations. 
The Fantasy sub-scale measures the ability to relate to fictional characters (e.g. books or movies). Items on these sub-scales 
are measured on a 5-point Likert-scale, with responses ranging between does not describe me well, to describes me very 
well
Empathy Quotient (EQ) [36] [37]
A 60-item self-report scale. 40 items measure empathy on the cognitive and affective dimension and the remaining are 
included as control items. Each response is measured on a 4-point Likert scale, with responses ranging between strongly 
agree-to-strongly disagree
Questionnaire for 
Cognitive and Affective 
Empathy (QCAE)
[38] [17,39]
A 31-item self-report scale consisting of five sub-scales: Perspective-Taking and Online Stimulation, measuring cognitive 
empathy. Emotion Contagion, Proximal Responsivity and Peripheral Responsivity measuring affective empathy
The Perspective-Taking sub-scale measures a respondent’s ability to understand the perspective of others. The Online 
Stimulation sub-scale measures how well a respondent can mentally represent another’s emotional state. The Emotion 
Contagion taps into assessing the extent to which self-orientated emotions match the affective state of others. The Proximal 
Responsivity sub-scale examines a respondent’s emotional response to the moods of significant others (e.g. friends) and the 
Peripheral Responsivity sub-scale measures affective responsiveness to detached, or fictional social context (e.g. characters 
in movies, plays, books etc). Items on these subscales are measured on 4-point Likert scale, with responses ranging 
between describes me very well to does not describe me well
Balanced Emotional 
Empathy Scale (BEES) [40] [41]
A 30-item self-report scale measuring spontaneous, or vicarious emotional reactions in response to another’s emotional 
distress (i.e. affective/emotional empathy). Each itemis rated on a 9-point extent to which you agree-disagree spectrum
Questionnaire Measure 
of Emotional Empathy 
(QMEE) (also referred 
to as the emotional em-
pathic tendency scale)
[42] [43]
A 33-item self-report scale assessing affective role-taking empathy. In other words, this scale measures the extent to which 
the respondent agrees with the self-orientated emotional responses someone would typically experience in response to 
another’s emotional distress. Items on this scale are measured on a 4-point Likert scale, ranging between strongly agree to 
strongly disagree
Social context emotional 
recognition task [44] [44]
In this task, participants watched short films representing a happy, sad, angry and fearful context. Participants rated their 
emotional reaction (affective empathy) to each film and the intensity of the emotion they felt using a rating scale. The 
rating scale consisted of a continuous 10 cm line on which participants had to make a mark: Scores to the extreme left 
corresponded to the lowest intensity (0 cm) and scores to the extreme right corresponded to the highest intensity
Table S1: List of empathy measures used by studies included in the meta-analysis.
Symptom Assessment Measure
Studies in me-
ta-analysis
Description of Measure
Positive and Negative Syndrome Scale 
(PANSS) [45] [2-44]
A 30-item semi-structured measure completed by clinicians in an interview or observation format. 7 items mea-
sure positive symptoms of schizophrenia, 7 items measure negative symptoms and 16 items measures general 
psychopathology
Schedule for the ASSESSMENT of Positive 
Symptoms(SAPS) [46] [23-25,29,30,32,41]
A 34-item clinician rated scale which is used to measure the following positive symptoms: Bizarre behaviour, 
formal thought disorder, hallucinations and delusions
Schedule for the Assessment of Negative Symp-
toms (SANS) [47]
[17,23-
25,29,30,32,41]
The originally published scale consisted of 25 items. Currently, SANS comprises of 19-items, representing 5 
scales: Blunted/flattened affect, alogia, avolition-apathy, anhedonia/associability and inattention. Items on this 
scale are rated by clinicians
Brief Psychiatric Rating Scale (BPRS)-positive 
symptom sub-scale [48] [16,17,20]
A 24-item scale assessing positive symptoms of schizophrenia via self-report and clinical observations. Each 
item on this scale is measured on a 2 (very mild) to 7 (extremely severe) anchor points
BPRS-Negative symptom subscale [48] [16,20] This sub-scale consists of items assessing negative symptoms of schizophrenia and is measured in the same way as the BPRS-positive symptom sub-scale
Table S2: List of symptom assessments used by studies included in the meta-analysis.
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Neurocognitive Domain Neurocognitive Measures Description of Measure
Studies in Meta-
Analysis
Attention/ Vigilance (re-
ported by three studies)
The test of everyday attention [49]
This test included three tasks:
1. Visual selective attention task. This task involved searching a map for 2 minutes.
2. Auditory selective attention task. In this task participants must count the number of times 
they hear a tone while ignoring a distracting tone of a higher intensity.
3. Sustained visual attention task-The Visual elevator task. In this task participants are pre-
sented with an elevator which they are told represents floors. Participants are instructed to 
count the number of elevator doors they pass
[41]
Continuous performance task-iden-
tical pairs [50]
A computerised test assessing sustained attention. A button must be pressed each time the 
participant sees two numbers matching onscreen [6,29]
2. Verbal learning (report-
ed by six studies)
Hopkins verbal learning test-re-
vised [51]
The task administrator presents 12 words from three categories (e.g. animal, colours and 
numbers). Participant is assessed on how many words they can recall after each of three 
learning trials
[6,7,15]
Rey auditory verbal learning test 
(English version) [52]
Participants are presented with 15 words over five trials. Participants must say the words 
immediately. An interference trial is then presented which involved presenting new words. 
Participants are asked to recall words from the initial list presented
[26,43]
California verbal learning test-sec-
ond edition [53]
Participants are presented with a list of 16 words which they recall immediately over five 
trials. This is followed by an interference list, in which 16 words are presented in a single trial 
which must be recalled immediately. 20 minutes later a recognition trial is administered. Recall 
can be free or category-cued
[29]
3a. Working Memory 
(verbal) (Reported by 
Five Studies)
Wechsler memory scale-third 
edition (WMS-III): Letter-number 
span [54]
Participants are instructed to mentally re-order strings of numbers and letters and repeat them 
orally to the test administrator [6,15,24,29]
WAIS Digit Span Forward/Back-
wards Subtest [55]
Participants are instructed to repeat the numbers presented to them either in the same or 
reverse order. Over the course of the task, the number sequence increases
[29]
Repeatable battery for the 
assessment of neuropsychological 
status-story memory sub-test [56]
A 12-item short story is presented visually in three separate parts over two trials. Each story is 
read aloud with a low reading speed. Participants recall as much of the story as they can after 
each presentation. A verbatim criterionis used to score participant response
[25]
3b. Working memory
(non-verbal) (reported by 
five studies)
WAIS-Revised (R)-working mem-
ory subtest [57]
This test uses an arithmetic and digit span test. For the digit span test, participant recalls a 
series of number in a specific order (i.e., ascending, backward or same order). For the arithme-
tic test, participants work within a specified time limit to mentally resolve a series of mental 
arithmetic problems
[28]
WMS-III: Spatial span [54]
Participants are presented with 12 blocks on which a sequence is tapped by the administrator. 
Participants must tap the blocks in the order requested by the administer (either reverse or 
same order)
[7,15,29]
Short recognition memory test for 
faces [58]
Participants are presented with 25 grey scale faces of male actors at a rate of 1 face every 3 
seconds. Participants decide (using a forced choice option) whether the image presented is 
pleasant or unpleasant immediately post stimulus onset. Each stimulus item is paired with a 
distractor item
[41]
4. Speed of processing 
(reported by eight studies)
Trail Making Test A (TMT A) [59] In this test, numbers a placed irregularly on a sheet of paper, which participants are instructed 
to join correctly? This is a timed pencil and paper test
[6,15,28,29,43]
Trail Making Test B (TMT B) [59] In part B, participants are presented with numbers and letters in random order, which they connect in alternating order [28,43]
Brief Assessment of Cognition in 
Schizophrenia (BACS): Symbol 
coding [60]
This is a timed test in which participants are required to write down the digit corresponding to 
nonsense symbols within 90 seconds [6,15]
WAIS-III Digit symbol substitu-
tion sub-test [55]
Participants are presented with a series of numbers and symbols in a grid. Participants repro-
duce symbols corresponding to the numbers in the grid within a 120 second time limit [29]
Category fluency-animal subtest 
[61]
In this test, participants are instructed to generate exemplars of animals within 60 seconds. The 
total number of true animal exemplars within the time frame is measured [6,15,29]
Five-point test [62]
There are two parts to this test: Verbal and non-verbal. In the verbal test participants must 
make words that begin with a specific letter (e.g., “A”) within three minutes. Participants are 
instructed not to produce nouns or repeat words
In the non-verbal test participants are presented with 40 squares on a sheet of paper. Each 
square consists of 5 symmetrical dots. Within a 2-minute timeframe, participants must create 
as many designs as they can by joining the dots in each square with one or more straight lines
[14]
Repeatable battery for the 
assessment of neuropsychological 
status-coding sub-set [63]
A page filled with symbols is presented to participants. Each symbol corresponds to a number 
on top of the page. Participant must match the symbol to its corresponding number within 90 
seconds
[25]
5. Cognitive flexibility 
(reported by Three 
studies)
Stroop test [64]
There are three sub-tests to this task: The colour word sub-test in which participants must read 
the colour of the word presented in black ink. The colour name sub-test, in which participants 
must name the colour of the triangle, and in the interference sub-test, participants ignore the 
word they see and say the colour of the word (e.g. if the word black is written in the colour 
red, then the correct answer would be red)
[14,16]
Delis-kaplan executive function 
scale-colour word interference 
sub-test [65]
In this test, a participant must inhibit a dominant and automatic verbal response of a word 
presented, and instead, name the colour of the ink for the word presented [24]
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6. Reasoning and problem 
solving (reported by six 
studies)
Tower of London Test [66]
Participants are presented with coloured beads arranged vertically on pegs of different heights. 
How they must be arranged,andthe number of moves allowed is determined by the experiment-
er, which they (the participant) must follow in order to achieve a specific arrangement
[21]
Neuropsychological assessment 
battery: Mazes sub-test [67]
Participants are presented with seven mazes, each increasing in difficulty. Participants com-
plete each maze within a 300-second time limit [6,15]
WAIS-III-Matrix reasoning sub-
test [55]
Participants are presented with different figures. Each figure must be analysed in order to 
determine which figure best fits the order of the sequence presented
[29]
Wisconsin card sorting test [68]
Participants sort a series of cards by a specific rule (e.g. by colour, shape or number of shapes). 
Feedback on performance is provided. After ten correct sorts, the rules for sorting are changed 
to a new rule without warning
[18,19]
7. Visual learning (report-
ed by three studies)
Brief visuospatial memory test-re-
vised [69] The instructor presents six geometric figures which participants reproduce from memory [6,15]
The Judgement of Line Orientation 
test [70]
Participants are presented with two angle lines. They are instructed to match the set to a set of 
11 lines by re-arranging them so that all the lines are 18 degrees apart and form a semi-circle [21]
Table S3: List of studies included in meta-analysis measuring neurocognition in schizophrenia and healthy controls
Noncognitive Domain Neuro-cognitive Measures Description of Task
Studies in Meta-Anal-
ysis
Pre-morbid verbal IQ 
(reported by 13 studies)
Multiple-choice vocabulary test 
(german version) [71]
This measure presents 37 rows of five words. From each row participants pick the actual word 
and rule out the pseudo-words. The number of correctly identified words provides the test 
result
[8,9,13,18,26-28]
National adult reading test [72]
This test comprises of 50 words with irregular spellings (e.g. aisle). Participants are assessed 
on their vocabulary comprehension rather than their ability to apply regular pronunciation 
rules
[11,22,24,25,32,39]
Verbal IQ (reported by 
two studies) WAIS-III- verbal subset [55] In this test, participants name the object in the picture or define the words presented to them [12,19]
Table S4: List of the studies in the meta-analysis measuring verbal comprehension in schizophrenia and healthy controls
Neuro-cognitive Domain Neurocognitive Measures
Studies in Meta-
Analysis
Description of General IQ Tests
General IQ (reported by 
10 studies)
Wechsler abbreviated adult intelli-
gence scale [73] [12,15,37]
The many versions of the Wechsler’s Adult Intelligence Scales measure a person’s ability to act 
purposefully, reason and deal effectively with his/her surrounding/environment [74]. This aim 
is fulfilled using several verbal ability and cognitive reasoning/style sub-tests (for a detailed de-
scription of each sub-test refer to Wechsler’s administration manual and scales [54,55,57,73,75]
Wechsler Adult Intelligence Scale 
III [55] [2,5,7,35]
Wechsler adult intelligence scale-
IV [75] [34]
Raven’s progressive matrices 
test [76] [21] This is a non-verbal group test designed to measure abstract reasoning
Groninger Intelligence Test [77] [43]
This test is used in the Netherlands as a reliable alternative to the Wechsler Adult Intelligence 
Tests. As such, this test includes examining the same cognitive and verbal abilities as the WAIS 
sub-tests [55]
Table S5: List of studies in the meta-analysis that examined general IQ
Cognitive Empathy k B SE 95% CI Z P I2
Age at Diagnosis 20 -0.06 0.018 [-0.09, -0.02] -3.35 0.0008 28.70
Duration of Illness 29 0.012 0.008 [0.001,0.03] 2.11 0.03 30.55
Positive symptoms 33 0.008 0.008 [-0.007,0.024] 1.004 0.31 30.73
Negative Symptom severity 33 0.004 0.007 [-0.009,0.01] 0.67 0.50 30.04
General Symptom Severity 15 0.01 0.01 [-0.01,0.03] 1.06 0.28 5.04
CPZ-Equivalent -mg/day 16 -0.0005 0.0006 [-0.001,0.0008] -0.77 0.43 13.50
Table S6: Moderating effect of clinical characteristics on the difference in performance between schizophrenia patients and healthy controls on cognitive 
empathy.
Note: K = Number of studies. B = regression coefficient. SE = standard error. 95% CI = 95% confidence interval. Z = indicates the extent of uncertainty in the 
regression coefficient. P = statistical significance, 2-tailed. I2 indicates the amount of between-study heterogeneity. CPZ-equivalent-mg/day = Chlorpromazine 
Equivalent, milligram per day.
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Affective Empathy k B SE 95% CI Z P I2
General IQ, Schizophrenia Spectrum Disorders 9 0.003 0.003 [-0.002,0.010] 1.12 0.25 4.98
Verbal IQ, Schizophrenia Spectrum Disorders 15 0.0001 0.002 [-0.005,0.005] 0.04 0.96 12.51
Global Neuro-cognition, Schizophrenia Spectrum Disorder 11 -0.004 0.008 [-0.020,0.012] -0.52 0.60 6.54
Table S7: Moderating effect ofneuro-cognitive abilities on the difference in performance between schizophrenia patients and healthy controls on cognitive 
empathy
Note: K = Number of studies. B = regression coefficient. SE = standard error. 95% CI = 95% confidence interval. Z = indicates the extent of uncertainty in 
the regression coefficient. P = statistical significance, 2-tailed. I2 indicates the amount of between-study heterogeneity. CPZ-equivalent-mg/day = Chlorprom-
azine Equivalent in milligram per day
Affective Empathy K B SE 95% CI Z P I2
Age, Schizophrenia spectrum 35 0.007 0.009 [-0.01,0.02] 0.79 0.42 32.38
Lower Education in Schizophrenia compared to Healthy Controls 21 -0.04 0.05 [-0.15,0.06] -0.75 0.45 18.47
Higher Proportion of Male Schizophreniathen Female Schizophrenia 28 0.003 0.005 [-0.006, 0.01] 0.71 0.47 26.14
Higher Proportion of Non-Caucasian Schizophrenia then Caucasian Schizophrenia 7 -0.0004 0.006 [-0.01,0.01] 0-0.06 0.94 5.05
Year of Study Publication 36 -0.02 0.02 [-0.06,0.02] -1.009 0.31 33.49
Table S8: Moderating effect of demographic variables on the difference in performance between schizophrenia patients and healthy controls on cognitive 
empathy
Note: K = Number of studies. B = regression coefficient. SE = standard error. 95% CI = 95% confidence interval. Z = indicates the extent of uncertainty in 
the regression coefficient. P = statistical significance, 2-tailed. I2 indicates the amount of between-study heterogeneity. CPZ-equivalent-mg/day = Chlorprom-
azine Equivalent in milligram per day
Affective Empathy K B SE 95% CI Z P I2
Age at Diagnosis 21 -0.02 0.02 [-0.08, 0.02] -1.01 0.31 23.26
Duration of Illness 32 0.007 0.01 [-0.01,0.02] 0.68 0.49 33.15
Severity of Positive Symptom 36 0.012 0.007 [-0.001,0.02] 1.68 0.09 39.85
Severity of Negative Symptoms 36 0.007 0.005 [-0.002,0.01] 1.52 0.12 39.60
Severity of General symptom 17 -0.004 0.01 [-0.03,0.02] -0.30 0.76 16.32
CPZ-Equivalent Mg/Day 18 -0.00015 0.0006 [-0.001,0.001] -0.24 0.80 4.97
Table S9: Moderating effect of clinical characteristics on the difference in performance between schizophrenia patients and healthy controls on affective 
empathy
Note: K = Number of studies. B = regression coefficient. SE = standard error. 95% CI = 95% confidence interval. Z = indicates the extent of uncertainty in 
the regression coefficient. P = statistical significance, 2-tailed. I2 indicates the amount of between-study heterogeneity. CPZ-equivalent-mg/day = Chlorprom-
azine Equivalent in milligram per day
Affective Empathy K B SE 95% CI Z P I2
General IQ, Schizophrenia 10 -0.0005 0.003 [-0.007,0.005] -0.17 0.85 54.02
Pre-morbid/Verbal IQ, Schizophrenia 15 -0.00009 0.002 [-0.005,0.005] -0.03 0.97 14.22
Global Neuro-cognition, Schizophrenia 13 -0.005 0.005 [-0.016,0.005] -1.03 0.29 7.01
Table S10: Moderating effect of cognition on the difference in performance between schizophrenia patients and healthy controls on affective empathy
Note: K = Number of studies. B = regression coefficient. SE = standard error. 95% CI = 95% confidence interval. Z = indicates the extent of uncertainty in 
the regression coefficient. P = statistical significance, 2-tailed. I2 indicates the amount of between-study heterogeneity. CPZ-equivalent-mg/day = Chlorprom-
azine Equivalent in milligram per day
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Affective Empathy K B SE 95% CI Z P I2
Age, Schizophrenia 36 0.01 0.01 [-0.005,0.03] 1.43 0.15 39.60
Fewer Years in Education in Schizophrenia compared to Healthy Controls 23 -0.04 0.07 [-0.19,0.10] -0.55 0.57 25.46
Higher Proportion of Male Schizophrenia then Female Schizophrenia 29 -0.001 0.006 [-0.01,0.01] -0.30 0.76 31.43
Higher Proportion of Non-Caucasian Schizophrenia compared to Caucasian Patients 7 0.005 0.007 [-0.009,0.021 0.74 0.45 5.28
Year of Study Publication 39 -0.04 0.02 [-0.09,0.008] -1.65 0.09 41.16
Table S11: Moderating effect of demographic variables on the difference in performance between schizophrenia patientsand healthy controls on affective 
empathy
Note: K = Number of studies. B = regression coefficient. SE = standard error. 95% CI = 95% confidence interval. Z= indicates the extent of uncertainty in the 
regression coefficient. P = statistical significance, 2-tailed. I2 indicates the amount of between-study heterogeneity. CPZ-equivalent-mg/day =Chlorpromazine 
Equivalent in milligram per day
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